Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q4 FY2017 Earnings Presentation
15 slides from Advanced Enzyme Technologies's earnings presentation, May 2017
Slide 1: Where Enzyme is Life – Earnings Presentation Q4FY17
Where ENZYME is life EARNINGS PRESENTATION Q4FY17
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview: What are enzymes?
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed pure enzyme player globally 2nd 2nd 3,314 2,204 Amongst Top 15 Global Enzyme Companies Manufacturing Units – 7 R&D Units – 5 FY 2013 FY 2017 India - 5 USA - 2 Ind
Slide 5: Board of Directors
Board of Directors Mr. Vasant Rathi Mr. C L Rathi Mrs. Savita Rathi Mr. Mukund M. Kabra Chairman and Non- Executive Director Managing Director Whole-time Director Whole-time Director Mr. Vasant Laxminarayan Rathi is the Mr. Chandrakant Laxminarayan Rathi, is the Mrs. Savita Chandrakant Rathi, is the
Slide 6: Management Team
Management Team A double graduate, Piyush first completed his Bachelors in Maths from Mumbai University and then in Finance from Michigan Tech University, USA. Subsequently he completed his MBA from SCMHRD and joined Advanced Enzymes in April 2005. In 2007 and in 2010, Piyush took charge of the Huma
Slide 7: Results Summary – FY17
Results Summary – FY17 Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 3,314 1,389 1,530 924 2,938 768 FY16 FY17 FY16 FY17 FY16 FY17 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Food Industrial Processing 8% -3% 12% 21% 35% FY17 512 2,386 223 193 FY16 474 2,137 184 143 Note: On Consolidated B
Slide 8: Results Summary – Q4FY17
Results Summary – Q4FY17 Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 860 401 227 805 333 200 Q4FY16 Q4FY17 Q4FY16 Q4FY17 Q4FY16 Q4FY17 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Food Industrial Processing -24% 19% (0.3%) 55% 46% Q4FY17 144 616 59 41 Q4FY16 121 618 38 28 Note: On Consoli
Slide 9: Revenue Split
Revenue Split Q4FY17 FY17 Segmental Revenue Split (%) Segmental Revenue Split (%) 5% 6% 15% 7% 17% 7% 71% 72% Animal HC Human HC Food Industrial Processing Animal HC Human HC Food Industrial Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 42% 52% 38% 46% 4% 4% As
Slide 10: Profit & Loss (Consolidated) – Q4FY17 & FY17
Profit & Loss (Consolidated) – Q4FY17 & FY17 ₹ in Million except per share data Q4FY17 Q3FY17 Q4FY16 Particulars Y-o-Y (%) FY17 FY16 Y-o-Y (%) Unaudited Unaudited Unaudited Income from Operations 860 600 805 7% 3,314 2,938 13% Expenses 565 441 432 31% 1,929 1,649 17% Profit from Operations before Ot
Slide 11: Balance Sheet (Consolidated) – FY17
Balance Sheet (Consolidated) – FY17 ₹ in Million Particulars FY17 FY16 EQUITY AND LIABILITIES Share capital 223 218 Reserves and surplus 4,332 2,563 Minority interest 124 54 Long-term borrowings 197 388 Other - Non-current liabilities 191 176 Short-term borrowings 265 296 Trade payables 110 115 Othe
Slide 12: Financial Performance – FY17
Financial Performance – FY17 ₹ in Million Revenue from Operations 2500 EBIDTA & EBIDTA Margin (%) 48% 47% 3,314 46% 47% 2,938 2000 46% 2,394 43% 45% 2,204 2,231 1500 43% 1530 44% 1000 42% 1,389 43% 943 1,031 931 42% 41% 500 40% 0 39% FY 13 FY 14 FY 15 FY 16 FY 17 FY 13 FY 14 FY 15 FY 16 FY 17 EBIDTA
Slide 13: Strong Financial Performance – FY17
Strong Financial Performance – FY17 Net Working Capital (Days) Net Worth (₹ mn) 128 4,555 119 2,781 112 110 109 2,120 1,634 1,674 FY 13 FY 14 FY 15 FY 16 FY 17 FY 13 FY 14 FY 15 FY 16 FY 17 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 1.1 31% 28% 1.0 26% 27% 25% 28% 0.5 24% 20% 0.4 13% 0.1 FY 13 FY
Slide 14: Shareholder Information
Shareholder Information Stock Data (As on 31st March 2017) Top Institutional Holders Market Capitalization (₹) 45,992 mn Institutions OS (%) DSP Blackrock Investment Management Co. 3.89 Shares Outstanding 22.3 mn Motilal Oswal Asset Management Co. Ltd. 1.42 Free Float 6.5 mn Reliance Capital Trustee
Slide 15: Thank You
Thank You Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q4 FY2017 Earnings Presentation on 6ix